Thursday, 25 Apr 2019

You are here

Fish Oil Fails in Dry Eye Trial

Many topical and OTC products are recommended when treating chronic dry eyes, including omega-3 fatty acids (fish oil or n−3 fatty acids) to relieve symptoms; the NEJM reports that the DREAM trial shows no clinical benefit of n−3 fatty acids for 12 months when compared to placebo.

Patients (n=535) with moderate-to-severe dry eye disease were randomized (2:1) to receive daily oral dose of 3000 mg of fish-derived n−3 eicosapentaenoic and docosahexaenoic acids or an olive oil placebo (placebo group). The primary outcome was the mean change from baseline in the score on the Ocular Surface Disease Index (OSDI; scores on a 0 to 100 scale.

At 12 months, the mean change in the OSDI (dry eye) score was not significantly different between the active supplement group and the placebo group (−13.9 points and −12.5 points, respectively (P=0.21). Likewise there were no differences in secondary outcomes (conjunctival staining score, corneal staining score, tear break-up time or Schirmer’s test).

Rates of adverse events were similar in the two trial groups.

Patients with chronic dry eys treated with n-3 fatty acids failed to achieve significantly better outcomes than those on placebo. (DREAM ClinicalTrials.gov number, NCT02128763.)

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Timing of Shoulder Injections Impacts Surgical Infection Risk

A study of patients undergoing arthroscopic rotator cuff repair shows that corticosteroid injections in the month prior to surgery are associated with a significantly increased risk of surgical site infection.

Dietary Supplements Fail to Reduce Mortality Risks

An NIH funded prospective study has shown that the use of daily dietary supplements was not associated with a subsequent lowering of mortality risk.

An Autoimmune Diagnosis Alters Perceptions of Pregnancy and Lactation

A study from UT Southwestern and the Baylor Research Institute examined the preceptions and practices of women with autoimmune or inflammatory rheumatic diseases (AIRD) noting that an AIRD diagnosis changed most womens future hopes and plans regarding pregnancy and lactation.

ACR Position Statements on Drug Pricing and Step Therapy

The American College of Rheumatology Committee on Rheumatologic Care has released new drug pricing and step therapy position statements that they hope legislators will consider as they continue to explore policy and regulatory options to make drugs more affordable and accessible.  

CRA Position Statement on Medical Cannabis Use

Courtesy of the Canadian Rheumatology Association (CRA) website, here are consensus guidelines on medical cannabis use.

Rheumatology patients experience prevalent pain that is only modestly controlled with current treatment strategies.